gefitinib has been researched along with plx4032 in 12 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,657 | 103 | 1,587 |
| Protein | Taxonomy | gefitinib (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chang, Y; Cheng, H; Ding, K; Lu, J; Lu, X; Luo, J; Ren, X; Tu, Z; Zhang, L; Zhang, Q | 1 |
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
| Bantscheff, M; Bergamini, G; Gohlke, B; Gupta, V; Handa, H; Heinzlmeir, S; Helm, D; Klaeger, S; Kuster, B; Médard, G; Perrin, J; Preissner, R; Qiao, H; Savitski, MM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Alsaghir, FM; El-Gamal, MI; Sbenati, RM; Semreen, AM; Semreen, MH; Shehata, MK | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Nishio, K; Togashi, Y | 1 |
| Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L | 1 |
| Beloueche-Babari, M; Delgado-Goñi, T; Galobart, TC; Leach, MO; Normantaite, D; Wantuch, S; Whittaker, SR | 1 |
| Flaherty, K; Guhan, S; Ji, Z; Kumar, R; Njauw, CN; Rajadurai, A; Reddy, B; Tsao, H | 1 |
3 review(s) available for gefitinib and plx4032
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Imidazoles; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Structure-Activity Relationship; Thiazoles; Tubulin | 2021 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
9 other study(ies) available for gefitinib and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indicators and Reagents; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2014 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib | 2018 |
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dinoprostone; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mitochondria; Mutation; Prostaglandin-E Synthases; Proto-Oncogene Proteins B-raf; Pyruvate Carboxylase; Signal Transduction; Skin Neoplasms; Vemurafenib | 2020 |
Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HEK293 Cells; Humans; Melanoma; Mice; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Signal Transduction; Up-Regulation; Vemurafenib | 2021 |